FDA Approves Self-administered, SubQ Furosemide Preparation
-
The US Food and Drug Administration (FDA) has approved a furosemide preparation (Furoscix, scPharmaceuticals) intended for subcutaneous self-administration by outpatients with chronic heart failure (HF) and volume overload, the company has announced. The product is indicated for use with a SmartDose On-Body Infuser (West Pharmaceutical Services) single-use subcutaneous administration device, which affixes to the abdomen.
-
@margie The infuser is loaded by the patient or caregiver with a prefilled cartridge and is programmed to deliver Furoscix 30 mg over 1 hour followed by a 4-hour infusion at 12.5 mg/h, for a total fixed dose of 80 mg, scPharmaceuticals said in a press release on the drug approval. Furosemide, a loop diuretic and one of the world's most frequently used drugs, is conventionally given intravenously in the hospital or orally on an outpatient basis.